PREVAIL Study
Principal Investigator
Prof. Dr. Ahmet Dirican, MD, PhDMedical Oncology
Menu
Phase II–III clinical trials
Clinical research
Extensive experience in Phase II and Phase III oncology clinical trials, with active involvement as Principal Investigator and Sub-Investigator in international and multicenter studies across a range of solid tumors.
Clinical Research
Clinical research
Advancing precision oncology through rigorous clinical research, molecular profiling, and biomarker-driven treatment strategies.
Extensive experience in Phase II and Phase III oncology clinical trials, with active involvement as Principal Investigator and Sub-Investigator in international and multicenter studies across a range of solid tumors.
AMPLITUDE Study
Principal Investigator
CodeBreaK 201
Principal Investigator
61186372PANSC2002 · POLYDAMAS
Principal Investigator
78278343PCR3003 · KLK2-PASenger
Principal Investigator
ATHENA Study
Sub-Investigator
ANNAR Study
Sub-Investigator
MX39897 Study
Solid-tumor molecular profiling
Phase II–III Clinical Trials
International and multicenter oncology drug-development studies.
Precision Oncology & Biomarker-Driven Trials
Integrating molecular biomarkers and genomic information into treatment selection.
Next-Generation Sequencing & Molecular Profiling
Exploring the clinical value of comprehensive genomic profiling in patients with solid tumors.
Emerging Cancer Therapeutics
Clinical investigation of targeted therapies, immunotherapy, and novel treatment strategies.
Good Clinical Practice
TransCelerate BioPharma GCP — Investigator Version 2.1 · 2025
ICH GCP E6(R3) — Global Health Training Centre · 2026